Federated Hermes
RCUS icon

Federated Hermes’s Arcus Biosciences RCUS Stock Holding History

Federated Hermes’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5K Sell
1,410
-21,809
-94% -$471K ﹤0.01% 1738
2025
Q4 		$553K Buy
23,219
+21,648
+1,378% +$442K ﹤0.01% 1281
2025
Q3 		$21.4K Sell
1,571
-138
-8% -$1.44K ﹤0.01% 1797
2025
Q2 		$13.9K Sell
1,709
-434
-20% -$3.71K ﹤0.01% 1765
2025
Q1 		$16.8K Sell
2,143
-750
-26% -$8.7K ﹤0.01% 1750
2024
Q4 		$43.1K Sell
2,893
-285
-9% -$4.65K ﹤0.01% 1707
2024
Q3 		$48.6K Buy
+3,178
New +$50.1K ﹤0.01% 1668
2023
Q4 		– Sell
-1,095
Closed -$19.7K – 2179
2023
Q3 		$19.7K Sell
1,095
-38,273
-97% -$769K ﹤0.01% 1766
2023
Q2 		$800K Buy
39,368
+34,915
+784% +$665K ﹤0.01% 1210
2023
Q1 		$81.2K Buy
4,453
+2,203
+98% +$42.1K ﹤0.01% 1690
2022
Q4 		$46.5K Buy
2,250
+126
+6% +$3.47K ﹤0.01% 1722
2022
Q3 		$56K Buy
+2,124
New +$56.2K ﹤0.01% 1658
2022
Q2 		– Sell
-3,541
Closed -$111K – 2255
2022
Q1 		$111K Sell
3,541
-10,137
-74% -$340K ﹤0.01% 1651
2021
Q4 		$553K Buy
13,678
+8,205
+150% +$318K ﹤0.01% 1456
2021
Q3 		$191K Buy
5,473
+5,217
+2,038% +$162K ﹤0.01% 1669
2021
Q2 		$7K Sell
256
-189,137
-100% -$5.4M ﹤0.01% 2012
2021
Q1 		$5.32M Buy
189,393
+188,881
+36,891% +$6.57M 0.01% 837
2020
Q4 		$13K Sell
512
-116,773
-100% -$2.83M ﹤0.01% 1951
2020
Q3 		$2.01M Buy
117,285
+65,060
+125% +$1.45M ﹤0.01% 986
2020
Q2 		$1.29M Sell
52,225
-45,182
-46% -$1.22M ﹤0.01% 1157
2020
Q1 		$1.35M Buy
97,407
+91,309
+1,497% +$1.14M ﹤0.01% 1016
2019
Q4 		$62K Sell
6,098
-407
-6% -$3.42K ﹤0.01% 1720
2019
Q3 		$59K Sell
6,505
-82
-1% -$659 ﹤0.01% 1706
2019
Q2 		$53K Buy
6,587
+840
+15% +$8.41K ﹤0.01% 1668
2019
Q1 		$72K Buy
5,747
+2,038
+55% +$22.1K ﹤0.01% 1623
2018
Q4 		$40K Sell
3,709
-232
-6% -$2.71K ﹤0.01% 1683
2018
Q3 		$55K Buy
+3,941
New +$50.3K ﹤0.01% 1726

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Federated Hermes's RCUS Position: Q1 2026 in Review

Federated Hermes reduced its Arcus Biosciences (RCUS) stake by 94% in Q1 2026, selling an estimated $471K and leaving 1,410 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1738.

Federated Hermes first reported a position in RCUS in Q3 2018 and has held it in 27 quarters since. The position peaked at $5.32M in Q1 2021. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Federated Hermes held 1,410 shares of Arcus Biosciences worth $30.5K as of Q1 2026.
  • Federated Hermes sold 21,809 Arcus Biosciences shares in Q1 2026, an estimated $471K.
  • Arcus Biosciences made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1738 holding.
  • Federated Hermes first reported a position in Arcus Biosciences in Q3 2018 and has held it in 27 quarters since.
  • Federated Hermes's Arcus Biosciences position peaked at $5.32M in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.